Newswire (Published: Monday, June 17, 2019, Received: Monday, June 17, 2019, 7:27:07 PM CDT)

Word Count: 489

2019 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Ivy League Daily News -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating in Philadelphia, United States, by NewsRx journalists, research stated, “Retrospective data suggest less benefit from androgen deprivation therapy (ADT) in the setting of dose-escalated definitive radiation for prostate cancer, especially when a combination of external beam radiotherapy (EBRT) and brachytherapy approaches are used. This study aimed to test the hypothesis that patients with prostate cancer with intermediate- or high-risk disease undergoing extreme dose escalation with a brachytherapy boost are less likely to receive ADT.”

The news reporters obtained a quote from the research from the University of Pennsylvania, “Data from the National Cancer Database were extracted for men aged 40-90 years diagnosed with node-negative, non-metastatic prostate cancer from 2004 to 2015. Only patients with intermediate- or high-risk disease who were treated with definitive radiotherapy were included. The association and patterns of care between dose escalated radiotherapy and ADT receipt were assessed using multivariable logistic regression. Patients with unfavorable intermediate- and high-risk prostate cancer were significantly less likely to receive ADT if they underwent dose escalation with a combination of EBRT and brachytherapy (odds ratio 0.67, p< 0.0001). Over time, this decrease in ADT utilization has widened for patients with unfavorable intermediate-risk disease. There was no difference in ADT utilization when comparing patients treated with non-dose-escalated EBRT to those treated with dose-escalated EBRT (without brachytherapy). In this large national database, patients with unfavorable intermediate- and high risk prostate cancer were significantly less likely to receive guideline-indicated ADT if they underwent extreme dose escalation with combined radiation modalities.”

According to the news reporters, the research concluded: “As we await prospective data guiding the utility of ADT with dose escalated radiation, these findings suggest potential underutilization of ADT in patients at higher risk of advanced disease.”

For more information on this research see: Variations In Patterns of Concurrent Androgen Deprivation Therapy Use Based On Dose Escalation With External Beam Radiotherapy Vs. Brachytherapy Boost for Prostate Cancer. Brachytherapy, 2019;18(3):322-331. Brachytherapy can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA. (Elsevier - www.elsevier.com; Brachytherapy - http://www.journals.elsevier.com/brachytherapy/)

Our news correspondents report that additional information may be obtained by contacting J.J. Mohiuddin, University of Pennsylvania, Dept. of Radiation and Oncology, 3400 Civ Ctr Blvd, Trc 2 W, Philadelphia, PA 19104, United States. Additional authors for this research include S. Venigalla, N. Vapiwala and V. Narayan.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.brachy.2019.01.016. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of Pennsylvania

Places

North America
United States
Americas
New York
Pennsylvania
New York City
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Radiation Therapy